Harvard Bioscience, Inc. Share Price
Stocks
HBIO
US4169062043
Advanced Medical Equipment & Technology
|
Delayed
Nasdaq
11:40:16 22/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 8.090 USD | +1.12% |
|
+1.12% | +20.96% |
| 12/08 | Harvard Bioscience, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 | CI |
| 11/08 | Harvard Bioscience, Inc., Q2 2026 Earnings Call, Aug 11, 2026 |
| Market Cap | 3.64Cr 3.18Cr 2.99Cr 2.73Cr 5.12Cr 348.15Cr 5.12Cr 36Cr 14Cr 177.79Cr 14Cr 13Cr 573.17Cr | P/E 2026 * |
-4.11x | P/E 2027 * | -17.2x |
|---|---|---|---|---|---|
| Enterprise Value | 3.64Cr 3.18Cr 2.99Cr 2.73Cr 5.12Cr 348.15Cr 5.12Cr 36Cr 14Cr 177.79Cr 14Cr 13Cr 573.17Cr | EV / Sales 2026 * |
0.41x | EV / Sales 2027 * | 0.39x |
| Free-Float |
90.61% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Nasdaq
| HBIO | Delayed | |
CBOE
| HBIO | Real-time |
Last Transcript: Harvard Bioscience, Inc.
| 1 day | +0.94% | ||
| 1 week | +1.12% | ||
| Current month | -0.25% | ||
| 1 month | +7.15% | ||
| 3 months | +33.61% | ||
| 6 months | +51.50% | ||
| Current year | +20.96% |
| 1 week | 7.9 |  | 8.19 |
| 1 month | 7.36 | | 8.4 |
| Current year | 4 | | 8.4 |
| 1 year | 3.76 | | 9.4 |
| 3 years | 2.81 | | 55.6 |
| 5 years | 2.81 | | 82.3 |
| 10 years | 2.81 | | 87.5 |
| Manager | Title | Age | Since |
|---|---|---|---|
John Duke
CEO | Chief Executive Officer | 55 | 28/07/2025 |
Mark Frost
DFI | Director of Finance/CFO | 63 | 12/05/2025 |
Diane Houston
CTO | Chief Tech/Sci/R&D Officer | - | 01/04/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Katherine Eade
BRD | Director/Board Member | 52 | 24/10/2017 |
John Duke
BRD | Director/Board Member | 55 | 02/06/2025 |
Robert Gagnon
BRD | Director/Board Member | 52 | 16/07/2025 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 20/03/26 | Free | Chief Executive Officer | 75,000 | 0.1677% | ||
| 20/03/26 | Free | Chief Financial Officer | 30,000 | 0.0671% | ||
| 17/03/26 | Buy | Director | 10,000 | 0.0224% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.12% | +1.12% | +69.74% | -80.22% | 3.64Cr | |
| -0.11% | +2.37% | +38.24% | +30.59% | 24TCr | |
| +2.52% | +5.96% | +16.47% | -10.69% | 15TCr | |
| -0.14% | +6.24% | -9.87% | +39.03% | 14TCr | |
| +2.29% | +2.03% | -53.87% | -16.49% | 6.34TCr | |
| +0.87% | +3.98% | +20.88% | +27.98% | 5.09TCr | |
| -1.42% | -3.70% | -20.21% | -21.15% | 4.85TCr | |
| +2.56% | +10.66% | +31.63% | +49.26% | 4.57TCr | |
| +0.73% | +2.67% | +41.57% | +59.19% | 4.16TCr | |
| +3.33% | +10.93% | +142.96% | +86.19% | 3.61TCr | |
| Average | +1.25% | +4.24% | +27.76% | +16.37% | 8.23TCr | |
| Weighted average by Cap. | +0.96% | +5.46% | +18.72% | +22.52% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 8.98Cr 7.85Cr 7.38Cr 6.73Cr 13Cr 858.46Cr 13Cr 89Cr 34Cr 438.4Cr 34Cr 33Cr 1.41TCr | 9.46Cr 8.26Cr 7.77Cr 7.09Cr 13Cr 903.87Cr 13Cr 93Cr 36Cr 461.59Cr 36Cr 35Cr 1.49TCr |
| Net income | -89L -77.78L -73.1L -66.71L -1.25Cr -85Cr -1.25Cr -8.77Cr -3.39Cr -43Cr -3.34Cr -3.27Cr -140.07Cr | -22L -19.23L -18.07L -16.49L -30.95L -21Cr -30.95L -2.17Cr -83.68L -11Cr -82.62L -80.81L -35Cr |
| Net Debt | - | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 22/26/22 | $8.090 | +1.12% | 5,241 |
| 21/26/21 | $8.000 | +0.63% | 20,019 |
| 18/26/18 | $7.950 | -1.00% | 19,221 |
| 17/26/17 | $8.030 | +0.75% | 12,122 |
| 16/26/16 | $7.970 | -0.38% | 9,077 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- HBIO Stock
Select your edition
All financial news and data tailored to specific country editions
